• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Degarelix may be a treatment option for pedophilic disorder

byAlex ChanandRavi Shah, MD MBA
May 16, 2020
in Endocrinology, Pediatrics, Psychiatry, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Men with pedophilic disorder treated with gonadotropin-releasing hormone antagonist degarelix were at significantly lower risk of committing sexual abuse 2 weeks following initial injection, as measured by a composite risk score.

Evidence Rating: 1 (Excellent)

It is estimated that roughly half of child sexual offenders have pedophilic disorder, defined as recurrent sexual attraction to prepubescent children associated with distress or negative consequences. Prior literature have found that offenders often report long periods of struggle with sexual urges prior to first offence, suggesting a possible window for intervention before a crime is committed. Currently, treatment options are limited, with psychotherapy, testosterone-suppressing medications, and antidepressants being some of the few recommended intervention options. In this randomized clinical trial, researchers recruited 52 men with pedophilic disorder to investigate the possible efficacy of degarelix, a gonadotropin-releasing hormone antagonist to rapidly reduce the risk of committing child sexual abuse. Prior literature have found the drug to be effective in decreasing testosterone levels to castration levels within 3 days without causing a testosterone flare, which is associated with significant side effects, and as such, the drug was hypothesized as a potentially effective rapid-onset treatment option that would be relatively well tolerated. A composite risk score (range, 0-15 points) consisting of 5 domains (pedophilic disorder, sexual preoccupation, impaired self-regulation, low empathy, and self-rated risk) was derived to operationally define sexual abuse risk and used as the primary end point. The composite risk score decreased from 7.4 to 4.4 for the 25 participants assigned to receive 240mg of degarelix subcutaneously, and from 7.8 to 6.6 for the 26 participants in the placebo group, a significant mean between-group difference of –1.8 (95% CI, –3.2 to –0.5; P = .01) – a result that was still present at 10 weeks post injection. The drug was also found to be effective in the high risk group (defined as composite risk score >10), which achieved a composite score reduction of 3.3 points by week 2, compared to no change in the placebo group. The drug was well tolerated, with no major adverse events being recorded and the majority of adverse events being confined to the injection site. Although findings concerning the primary end point appear promising, it was noted that there was no significant difference in quality of life between the treatment and placebo groups at 2 and 10 weeks, indicating that quality of life in affected individuals are governed by more than the core symptoms of the disorder alone. Nevertheless, study findings are promising and suggest that degarelix, or other gonadotropin-releasing hormone antagonists may emerge as a novel treatment option for rapid risk reduction in individuals with pedophilic disorder.

Click to read the study in JAMA Psychiatry

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Testosterone treatment for hypogonadism did not reduce the risk of fractures

#VisualAbstract: Testosterone Treatment Does Not Reduce the Incidence of Fractures in Men with Hypogonadism

Testosterone-replacement therapy noninferior to placebo for preventing cardiovascular events

Tags: degarelixgonadotropingonadotropin-releasing hormone antagonistpedophiliatestosterone
Previous Post

#VisualAbstract: Efficacy and safety of landiolol for treatment of sepsis-related tachyarrhythmia

Next Post

#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19

RelatedReports

Casting versus surgery for ankle fractures in older adults
Chronic Disease

Testosterone treatment for hypogonadism did not reduce the risk of fractures

February 5, 2024
#VisualAbstract: Testosterone Treatment Does Not Reduce the Incidence of Fractures in Men with Hypogonadism
StudyGraphics

#VisualAbstract: Testosterone Treatment Does Not Reduce the Incidence of Fractures in Men with Hypogonadism

January 26, 2024
Cardiology

Testosterone-replacement therapy noninferior to placebo for preventing cardiovascular events

July 21, 2023
#VisualAbstract: Testosterone-replacement therapy for middle-aged and older men with hypogonadism does not increase risk of adverse cardiac events
StudyGraphics

#VisualAbstract: Testosterone-replacement therapy for middle-aged and older men with hypogonadism does not increase risk of adverse cardiac events

June 21, 2023
Next Post
#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19

#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19

Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces

Renin-angiotensin-aldosterone system inhibitors do not affect COVID-19 risk

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

Remdesivir in adults with severe COVID-19

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
  • #VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.